Stanley Abel

SiteOne Therapeutics, Inc. develops novel pain therapeutics and diagnostics. Its therapeutic candidates are selective inhibitors of a voltage-gated sodium ion channel. The company was founded by Sandip Biswal, Justin Du Bois, George Miljanich, John Mulcahy and David Yeomans in 2010 and is headquartered in Bozeman, MT.

The Montana Bioscience Alliance serves as a hub for Montana’s biotechnology companies, entrepreneurs, laboratories, hospitals, clinics and universities to commercialize grow and sustain globally competitive bioscience companies. It Serve as the interface between the life sciences cluster and state government to help implement and improve the state’s life sciences cluster development strategy. The company was founded in 2004 and is headquartered in Billings, MT.

ProJenX, Inc. is a clinical-stage biotechnology company that focuses on developing targeted therapies for untreatable brain diseases, with a particular emphasis on ALS. The company is based in Nissequogue, NY. ProJenX's lead therapy candidate, Prosetin, is a first-in-class kinase inhibitor that is being developed for people living with ALS. The company's innovative, patient-specific, cell-based drug discovery platform is at the heart of its approach to research and drug development for ALS and other debilitating brain diseases. The company was founded in 2021 by Erin Fleming and Valerie Estess, and the CEO is Stan E. Abel.

Corthera, Inc. develops and manufactures pharmaceuticals, such as cardiovascular preparations. It engages in acquiring, developing, and commercializing therapies for illnesses in the acute care setting. The company was founded in 2003 and is headquartered in San Carlos, CA.

Cerexa, Inc. develops biopharmaceutical products. It is focuses on developing, acquiring and commercializing antibiotics to treat life-threatening, hospital-based infections. Cerexa's compound PPI-0903 is a cephalosporin used in treatment for complicated skin and skin-structure infections, as well as community-acquired and hospital-acquired pneumonias. The company was founded in 2005 and is headquartered in Alameda, CA.

Peninsula Pharmaceuticals, Inc. used to develop and commercialize antibiotics to treat life threatening infections. The company used to develop optimal anti-infective therapies that offer improved efficacy, dosing and safety characteristics over existing therapies. It was founded in 2001. The company was located in Alameda, CA.

Biotechnology Innovation Organization is the world's biotechnology organization, providing advocacy, business development and communications services for more than 1,200 members worldwide. BIO members are involved in the research and development of innovative healthcare, agricultural, industrial and environmental biotechnology technologies. Corporate members range from entrepreneurial companies developing a first product to Fortune 100 multinationals. also represent state and regional biotech associations, service providers to the industry and academic centers.

Adynxx, Inc. develops clinical-stage pharmaceutical addressing pain at its molecular roots. Its technology platform provides treating the development of pain following surgery or trauma and established chronic pain syndrome. The company was founded by Julien Mamet in October 2007 and is headquartered in San Francisco, CA.